Product Code: RP-ID-10325856 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10325856
Market Overview:
Impact analysis of COVID-19 on Global Alzheimer’s Treatment Market Outlook 2027
Alzheimer’s Treatment Market Analysis – 2019-2027
According to the Alzheimer’s Association in 2020, an estimated 5.8 million people above the age of 65 in America are living with Alzheimer’s disease. This number is further predicted to increase to 13.8 million people above the age of 65 by 2050. Alzheimer’s disease is a neurological disorder which commonly occurs among the older population. The disease is characterized by the gradual degeneration of the brain tissue, which leads to temporary or permanent loss of memory. The Alzheimer’s treatment market is anticipated to grow at a CAGR of about 7.44% over the forecast period, i.e., 2020-2027. The market is further projected to attain a market value of around USD 2,008.17 million by the end of 2027.
The market for Alzheimer’s treatment is segmented by drug class, by distribution channel, by product, by end user and by region. On the basis of distribution channel, the market is segmented into online and offline segment. The offline segment is further segmented into hospital pharmacy and retail pharmacy, out of which, the offline distribution channel is anticipated to hold the leading share in the market on account of larger presence of hospital and retail pharmacies globally. On the other hand, the segment for online distribution channel is predicted to grow at the highest CAGR during the forecast period on account of rising demand for online pharmacies and various advancements in the e-commerce industry. The preference for online pharmacies is estimated to increase among the patients on account of various factors such as ease and convenience, confidentiality, low cost, and others.
Based on region, the Alzheimer’s treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America is anticipated to hold the major share of Alzheimer’s treatment market on account of increasing incidences of the disease. Moreover, the presence of key players in the region is another factor predicted to lead to the growth of North America Alzheimer’s treatment market in the coming years. The market in Europe is estimated to witness significant growth and hold a vast potential for the development of the Alzheimer’s treatment market on the back of its increasing geriatric population.
Some of the key industry leaders in the global Alzheimer’s treatment market are NeuroEM Therapeutics, Inc., AbbVie Inc., Allergan Inc., H. Lundbeck A/S, Janssen, Eli Lilly and Company, Daiichi Sankyo Company Limited, Eisai Co., Ltd. and Neuronix.
NeuroEM Therapeutics, Inc., AbbVie Inc., Allergan Inc., H. Lundbeck A/S, Janssen, Eli Lilly and Company, Daiichi Sankyo Company Limited, Eisai Co., Ltd. and Neuronix
Related Reports
Proof of Quality & Reliability
